Mon Sep 23 21:54:19 UTC 2024: ## Senate Hearing on High Drug Prices Sparks Heated Debate Between Chamber of Commerce and Advocacy Groups

**Washington D.C.** – The Senate Committee on Health, Education, Labor and Pensions (HELP) is set to hold a hearing tomorrow titled “Why Is Novo Nordisk Charging Americans with Diabetes and Obesity Outrageously High Prices for Ozempic and Wegovy?”. The hearing has already sparked a heated debate between the U.S. Chamber of Commerce and advocacy groups over the issue of drug pricing.

The Chamber of Commerce, in a letter addressed to Senator Bernie Sanders, criticized the hearing’s title as “blatantly biased” and accused Sanders of “berating, vilifying, and intimidating” Novo Nordisk. The Chamber strongly opposes Sanders’ proposed price controls on drugs, arguing that such measures would stifle innovation and research, ultimately leading to fewer new medicines and longer wait times for patients.

The Chamber’s letter cited a recent study that found price controls could lead to a 70% decrease in obesity-related clinical trials. They also claimed that the Inflation Reduction Act’s drug pricing program could result in a 29-44% drop in the development of new medicines.

On the other side of the debate, Doctors Without Borders/Médecins Sans Frontières (MSF) has called on pharmaceutical companies to lower their prices and stop blocking generic manufacturers from entering the market. They blame patents for the high prices, pointing to a study that showed insulin pens are sold for $2.98 in South Africa, $7.88 in India, and $28.40 in the US, compared to a potential cost-based price of $1.30 per pen.

MSF also claimed that GLP-1 medicines are sold at a nearly 40,000 percent markup in the US while remaining largely unavailable in low- and middle-income countries. They argue that the current pricing structure disadvantages patients and limits access to vital medication.

The upcoming hearing, featuring Novo Nordisk CEO Lars Fruergaard Jørgensen as the sole witness, is expected to be a heated discussion on the issue of drug pricing. While the Chamber advocates for market-oriented policies to lower drug prices, advocacy groups are pushing for stricter regulations and price controls to ensure affordable access to essential medications.

Read More